Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030375 | 0.89 | LMNA (0.35) | LMNA | |
| SCHEMBL3016228 | 0.86 | — | — | |
| SCHEMBL709500 | 0.85 | LMNA (0.41) | LMNA | |
| SCHEMBL3020430 | 0.85 | LMNA (0.41) | LMNA | |
| SCHEMBL3027892 | 0.81 | — | — | |
| SCHEMBL3026477 | 0.78 | — | — | |
| SCHEMBL3023746 | 0.78 | — | — | |
| SCHEMBL712295 | 0.78 | — | — | |
| SCHEMBL3019892 | 0.76 | POLB (0.31) | — | |
| SCHEMBL3013388 | 0.75 | LMNA (0.50) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200971-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2013-04-24 | — | — | EP | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| EP-2200655-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-18 | — | — | EP | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100233097-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20090098059-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-04-16 | — | — | US | disclosed |
| EP-2021317-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007133090-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221189-A1 | CONTRAST AGENTS | NR1I3, NR1I2, NR1D2 | LMNA 2753/4885 |
| US-20090098059-A1 | CONTRAST AGENTS | IPO4, IPO11, IPO8 | LMNA 1824/4885 |
| US-20100189656-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 1835/4885 |
| US-20100221192-A1 | CONTRAST AGENTS | C5, C1S, C1R | LMNA 1840/4885 |
| US-20100233097-A1 | CONTRAST AGENTS | C1R, C3AR1, CNKSR1 | LMNA 1939/4885 |
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | LMNA 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.